HLB PHARMACEUTICAL CO., LTD.
047920·KOSDAQ·6 grantsAmendments merged
- Shares granted, cumulative
- 1,160,000shares
- Next lockup release
- D-897
- 2029-02-02
Against the share price
At the 2026-08-18 close- Shares with a reason to exercise
- 390,000 shares
- 1.19% of shares outstanding
- Sellable right now
- 390,000 shares
- 100% of the shares with a reason to exercise
- Unrealized paper gain (to the employees)
- ₩998.4M
Potential dilution
Shares by strike price
- ₩17,374100K shares
- ₩14,782110K shares
- ₩12,361110K shares
- ₩8,740Latest price
- ₩6,180390K shares
Below the line (strike < Latest price) sits above the strike price: 390K shares, 55% of the shares still inside their exercise window.
Options the share price has risen past gain a reason to be exercised and sold once the lockup ends. Filings do not show what has already been exercised or forfeited, so these figures are on a cumulative grants basis and the shares actually outstanding may be fewer.
Share price vs. strike price
A strike price is fixed on the grant date; only the share price moves. Where the price line crosses a dashed line is when that block of options first had a reason to be exercised.
- Strike ₩6,180390K sharesabove
- Strike ₩14,782110K shares
- Strike ₩12,361110K shares
- Strike ₩17,374100K shares
Recipients by role
- Registered director5 people73%
- Unregistered officer5 people15%
- Employee7 people12%
- Other · unknown1 person0%
Sorted from the relation text written in the filings (18 recipients). Officers of affiliates and subsidiaries are counted as unregistered officers.
Shares granted by year
Cumulative grants per recipient
10 named · 4 withheld| Recipient | Shares, cumulative | Average strike | Exercisable | Paper gain |
|---|---|---|---|---|
| 310,00043.7% | ₩8,373 | 310,000 | ₩512M | |
| 100,00014.1% | ₩17,374 | 100,000 | — | |
| 50,0007.0% | ₩14,782 | 50,000 | — | |
| 40,0005.6% | ₩6,180 | 40,000 | ₩102.4M | |
| 40,0005.6% | ₩6,180 | 40,000 | ₩102.4M | |
| 30,0004.2% | ₩6,180 | 30,000 | ₩76.8M | |
| 20,0002.8% | ₩6,180 | 20,000 | ₩51.2M | |
| 20,0002.8% | ₩6,180 | 20,000 | ₩51.2M | |
| 20,0002.8% | ₩6,180 | 20,000 | ₩51.2M | |
| 20,0002.8% | ₩6,180 | 20,000 | ₩51.2M |
Recipients granted less than 10 in 10,000 of total shares issued have their names withheld under the disclosure rules; they cannot be split apart, so they are grouped into one row. Rows that pack several people onto one line, such as “OOO and 6 others”, are grouped there too, with the headcount read from that text — the split between them is never disclosed, so “my share” can only be prefilled with the per-person average. Filings carry no employee number or year of birth, so people with the same name are added together as one. “Exercisable” counts shares whose lockup has already ended, and any paper gain accrues to the employees holding the options.
Grant history · lockup schedule
Exercisable shares over time
It rises on the day a lockup ends and falls on the day an exercise window closes. Options actually exercised are not subtracted, because only executives have to report them.
20261 grant · 0 sharesReleases 2029-02-02
- Granted2026-02-02
- Exercise starts2029-02-02
- Exercise ends2033-02-02
- Shares granted
- —
- Strike price
- 18,611KRW
- Grant method
- New share issuance
- Approved by
- Board of directors
Below the strike priceShare price below the strike — no reason to exercise[Amended] Report on grant of stock options
20221 grant · 110,000 shares
- Granted2022-08-09
- Exercise starts2025-08-09
- Exercise ends2029-08-09
- Shares granted
- 110,000shares
- Strike price
- 14,782KRW
- Grant method
- New share issuance
- Approved by
- Board of directors
Below the strike priceShare price below the strike — no reason to exercise[Amended] Report on grant of stock options
20203 grants · 600,000 shares
- Granted2020-12-07
- Exercise starts2023-12-07
- Exercise ends2027-12-06
- Shares granted
- 100,000shares
- Strike price
- 17,374KRW
- Grant method
- New share issuance
- Approved by
- Board of directors
Below the strike priceShare price below the strike — no reason to exercise[Amended] Report on grant of stock options
- Granted2020-09-11
- Exercise starts2023-09-11
- Exercise ends2027-09-10
- Shares granted
- 110,000shares
- Strike price
- 12,361KRW
- Grant method
- New share issuance
- Approved by
- Board of directors
Below the strike priceShare price below the strike — no reason to exercise[Amended] Report on grant of stock options
- Granted2020-08-31
- Exercise starts2023-08-31
- Exercise ends2027-08-30
- Shares granted
- 390,000shares
- Strike price
- 6,180KRW
- Grant method
- New share issuance
- Approved by
- Board of directors
Above the strike price₩2,560 per share₩998.4M[Amended] Report on grant of stock options
20161 grant · 450,000 shares
- Granted2016-03-08
- Exercise starts2019-03-28
- Exercise ends2023-03-27
- Shares granted
- 450,000shares
- Strike price
- 11,390KRW
- Grant method
- New share issuance
- Approved by
- Board of directors
Below the strike priceShare price below the strike — no reason to exerciseReport on grant of stock options
Every figure here is parsed mechanically from the original DART filing (document.xml). “Exercise starts (estimated)” means the filing did not state an exercise period, so the date is the grant date plus two years under Article 340-2(4) of the Korean Commercial Act and may differ from the actual terms. Always read the original filing before making any decision.